Expression of IgG Monoclonals with Engineered Immune Effector Functions.

Area of Science:

• Biotechnology
• Immunology
• Molecular Biology

Background:

• Therapeutic antibody development relies on effective recombinant expression and characterization.
• Assessing Fc-mediated immune effector functions is crucial for antibody efficacy.
• Existing methods may not fully address the need for antibodies with modulated effector functions.

Purpose of the Study:

• To describe a method for cloning and mammalian expression of mouse and human IgG monoclonal antibodies.
• To engineer antibodies with reduced Fc-mediated immune effector functions by mutating Fc-gamma receptor and complement-binding sites.
• To produce antibody preparations suitable for preclinical evaluation in animal models.

Main Methods:

• Cloning of mouse and human IgG genes.
• Mammalian cell expression systems for recombinant antibody production.
• Site-directed mutagenesis to alter Fc-region binding sites for Fc-gamma receptors and complement.

Main Results:

• Successful recombinant expression of engineered mouse and human IgG monoclonals.
• Demonstrated reduction in Fc-mediated immune effector functions of the mutated antibodies.
• Characterization of antibody preparations showing low endotoxin levels.

Conclusions:

• The described method enables the generation of monoclonal antibodies with diminished immune effector functions.
• These engineered antibodies are suitable for in vivo studies, facilitating the investigation of their therapeutic potential.
• This approach supports the development of safer and more effective antibody-based therapies.